Is Tempus AI (TEM) A Bargain After Its Whole Genome Research Platform Push?

Tempus AI's new whole genome push and why it matters to investors

Tempus AI (TEM) is drawing fresh attention after announcing plans to build a research platform centered on 100,000 whole genomes, linked with detailed clinical histories and outcomes for AI driven disease research.

Tempus AI has seen a sharp reset in sentiment, with a 1 day share price return of 5.42% and a 30 day share price return of 19.41%. However, the year to date share price return is slightly down 0.24% and the 1 year total shareholder return is down 26.92%. This signals recent momentum building off a weaker longer term experience for holders.

Sprint ahead of the news cycle by comparing Tempus AI with a hand-picked group of other AI-driven healthcare companies using the 40 healthcare AI stocks.

After a 19.41% move over 30 days but a 1-year return still down 26.92%, Tempus AI sits at an awkward middle ground. Do the current valuation signals still lean in buyers' favour?

Most Popular Narrative: 18% Undervalued

Tempus AI last closed at $62.21, while the most followed narrative pegs fair value at $75.68, which points to a meaningful valuation gap that the market has yet to close.

Tempus AI is not simply an AI software business (not another ChatBot). It is building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect. The company generates revenue from multiple sources. Its Diagnostics business performs genomic testing for patients and providers, while its Data and Applications segment sells access to its massive de-identified datasets and AI powered tools to pharmaceutical companies, researchers, and healthcare organizations.

See why 26 investors see Tempus AI as 18% undervalued.

According to QuanD, the narrative assigns a fair value of $75.68 to Tempus AI, which sits roughly 18% above the latest closing price and reflects a view that the firm’s data flywheel and multi segment model justify a premium to where the shares trade today.

Result: Fair Value of $75.68 (UNDERVALUED)

Still, the Tempus AI story could be knocked off course if losses at the current scale persist or if high expectations for its AI platform cool meaningfully.

Find out about the key risks to this Tempus AI narrative.

Another view on Tempus AI's valuation

That 18% gap to the $75.68 fair value narrative is only one lens. Our DCF model offers a very different perspective, with Tempus AI trading at $62.21 compared with an estimated future cash flow value of $41.16. On this measure, the shares appear expensive.

DCF models place cash generation at the center of the analysis, so a $21.05 premium to the SWS DCF value highlights valuation risk if Tempus AI takes longer to reach profitability than some observers expect. When the signals diverge this clearly, investors need to consider which yardstick they find more persuasive.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Tempus AI for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 35 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on Tempus AI's value and risk profile do not have to leave you on the fence. Move quickly, review the numbers for yourself, and weigh both the potential upside and the concerns by checking the 1 key reward and 2 important warning signs.

Looking for more Tempus AI style investment ideas?

Do not stop your research with Tempus AI alone. Broaden your watchlist now, because the strongest opportunities often sit just outside the obvious names everyone is talking about.

• Target steady compounding by reviewing companies with strong balance sheets and fundamentals in the list of solid balance sheet and fundamentals (23 results).
• Hunt for quality at a discount by scanning the 15 high quality undiscovered gems before attention and expectations catch up.
• Prioritise resilience first and excitement second by focusing on 11 resilient stocks with low risk scores while others chase the story of the week.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com